NCT06471699View on ClinicalTrials.gov

The Effect of Continuous Glucose Monitoring in Individuals With Newly Diagnosed Type 2 Diabetes

NANot yet recruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2030

Conditions
Diabetes Type 2
Interventions
DEVICE

Continous Glucose Monitoring

The aim is to examine if the use of CGM will give the participants a significant support to implement lifestyle improvements in individuals with new on-set type 2 diabetes

OTHER

Self monitoring blood glucose

Capillary testing as in standard procedure

Sponsors

Collaborators (1)

Abbott Medical Devices
All Listed Sponsors
collaborator

The Swedish Research Council

OTHER_GOV

collaborator

Abbott Medical Devices

INDUSTRY

lead

Vastra Gotaland Region

OTHER_GOV

NCT06471699 - The Effect of Continuous Glucose Monitoring in Individuals With Newly Diagnosed Type 2 Diabetes | Biotech Hunter | Biotech Hunter